Neoadjuvant therapy of locally advanced gastric cancer

Journal of Surgical Oncology

Volumn 101, Issue 4, 2010, Pages 305-314

  Mezhir, James J ^a   Tang, Laura H ^a   Coit, Daniel G ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

Chemotherapy; Cytology; Gastrectomy; Gastric cancer; Neoadjuvant therapy

Indexed keywords

BIOLOGICAL MARKER; CISPLATIN; DOXORUBICIN; EPIRUBICIN; ETOPOSIDE; FLOXURIDINE; FLUORODEOXYGLUCOSE; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; METHOTREXATE; MITOMYCIN; VINBLASTINE;

ADJUVANT THERAPY; ADVANCED CANCER; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER SURGERY; CLINICAL TRIAL; CONTINUOUS INFUSION; HUMAN; MEDICAL LITERATURE; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; PATIENT CARE; PATIENT SELECTION; PERFORATION; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; REVIEW; RISK ASSESSMENT; STOMACH CANCER; TREATMENT OUTCOME; TREATMENT RESPONSE;

ALGORITHMS; ANTINEOPLASTIC AGENTS; DECISION TREES; GASTRECTOMY; HUMANS; NEOADJUVANT THERAPY; RADIOTHERAPY, ADJUVANT; STOMACH NEOPLASMS;

EID: 77749240282     PISSN: 00224790     EISSN: 10969098     Source Type: Journal    
DOI: 10.1002/jso.21483     Document Type: Review

References (60)

1. D'Angelica M, Gonen M, Brennan MF, et al.: Patterns of initial recurrence in completely resected gastric adenocarcinoma. Ann Surg 2004;240:808-816.
2. Bennett JJ, Gonen M, D'Angelica M, et al.: Is detection of asymptomatic recurrence after curative resection associated with improved survival in patients with gastric cancer? J Am Coll Surg 2005;201:503-510.
3. Janunger KG, Hafstrom L, Glimelius B: Chemotherapy in gastric cancer: A review and updated meta-analysis. Eur J Surg 2002;168:597-608.
4. Panzini I, Gianni L, Fattori PP, et al.: Adjuvant chemotherapy in gastric cancer: A meta-analysis of randomized trials and a comparison with previous meta-analyses. Tumori 2002;88:21-27.
5. Coit D: Adjuvant therapy for gastric cancer. J Am Coll Surg 2007;205:S54-S58.
6. Sun P, Xiang JB, Chen ZY: Meta-analysis of adjuvant chemotherapy after radical surgery for advanced gastric cancer. Br J Surg 2009;96:26-33.
7. Wagner AD, GrotheW, Behl S, et al.: Chemotherapy for advanced gastric cancer. Cochrane Database Syst Rev 2005; CD004064.
8. Cunningham D, Allum WH, Stenning SP, et al.: Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med 2006;355:11-20.
9. Fujimoto S, Watanabe Y, Enomoto K, et al.: Studies on preoperative cancer chemotherapy. Methods of preoperative intra-arterial infusion by the use of methotrexate or vinblastine. Cancer 1969;24:433-441.
10. Fujimoto S, Urushibara O, Watanabe Y, et al.: Studies on preoperative cancer chemotherapy. Effects of preoperative intraarterial infusion of methotrexate and mitomycin C on stomach cancer. Jpn J Surg 1971;1:72-82.
11. Fujimoto S, Akao T, Itol B, et al.: A study of survival in patients with stomach cancer treated by a combination of preoperative intra-arterial infusion therapy and surgery. Cancer 1976;37:1648-1653.
12. Stephens FO, Adams BG, Crea P: Intra-arterial chemotherapy given preoperatively in the management of carcinoma of the stomach. Surg Gynecol Obstet 1986;162:370-374.
13. Wilke H, Preusser P, Fink U, et al.: Preoperative chemotherapy in locally advanced and nonresectable gastric cancer: A phase II study with etoposide, doxorubicin, and cisplatin. J Clin Oncol 1989;7:1318-1326.
14. Plukker JT, Mulder NH, Sleijfer DT, et al.: Chemotherapy and surgery for locally advanced cancer of the cardia and fundus: Phase II study with methotrexate and 5-fluorouracil. Br J Surg 1991;78:955-958.
15. Ajani JA, Ota DM, Jessup JM, et al.: Resectable gastric carcinoma. An evaluation of preoperative and postoperative chemotherapy. Cancer 1991;68:1501-1506.
16. Leichman L, Silberman H, Leichman CG, et al.: Preoperative systemic chemotherapy followed by adjuvant postoperative intraperitoneal therapy for gastric cancer: A University of Southern California Pilot Program. J Clin Oncol 1992;10:1933-1942.
17. Crookes P, Leichman CG, Leichman L, et al.: Systemic chemotherapy for gastric carcinoma followed by postoperative intraperitoneal therapy: A final report. Cancer 1997;79:1767-1775.
18. Ajani JA, Mayer RJ, Ota DM, et al. Preoperative and postoperative combination chemotherapy for potentially resectable gastric carcinoma. J Natl Cancer Inst 1993;85(22):1839-1844.
19. Persiani R, Rausei S, Pozzo C, et al. 7-Year survival results of perioperative chemotherapy with epidoxorubicin, etoposide, and cisplatin (EEP) in locally advanced resectable gastric cancer: up-to-date analysis of a phase-II study. Ann Surg Oncol 2008;15(8):2146-2152.
20. Yoshikawa T, Sasako M, Yamamoto S, et al. Phase II study of neoadjuvant chemotherapy and extended surgery for locally advanced gastric cancer. Br J Surg 2009;96(9):1015-1022
21. Newman E, Marcus SG, Potmesil M, et al.: Neoadjuvant chemotherapy with CPT-11 and cisplatin downstages locally advanced gastric cancer. J Gastrointest Surg 2002;6:212-223. Discussion 223.
22. Kelsen D, Karpeh M, Schwartz G, et al.: Neoadjuvant therapy of high-risk gastric cancer: A phase II trial of preoperative FAMTX and postoperative intraperitoneal fluorouracil-cisplatin plus intravenous fluorouracil. J Clin Oncol 1996;14:1818-1828.
23. Schuhmacher CP, Fink U, Becker K, et al.: Neoadjuvant therapy for patients with locally advanced gastric carcinoma with etoposide, doxorubicin, and cisplatinum. Closing results after 5 years of follow-up. Cancer 2001;91:918-927.
24. Brenner B, Shah MA, Karpeh MS, et al.: A phase II trial of neoadjuvant cisplatin-fluorouracil followed by postoperative intraperitoneal floxuridine-leucovorin in patients with locally advanced gastric cancer. Ann Oncol 2006;17:1404-1411.
25. Macdonald JS, Smalley SR, Benedetti J, et al.: Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. N Engl J Med 2001;345:725-730.
26. Lowy AM, Feig BW, Janjan N, et al.: A pilot study of preoperative chemoradiotherapy for resectable gastric cancer. Ann Surg Oncol 2001;8:519-524.
27. Allal AS, Zwahlen D, Brundler MA, et al.: Neoadjuvant radiochemotherapy for locally advanced gastric cancer: Long-term results of a phase I trial. Int J Radiat Oncol Biol Phys 2005;63:1286-1289.
28. Roth AD, Allal AS, Brundler MA, et al.: Neoadjuvant radiochemotherapy for locally advanced gastric cancer: A phase I-II study. Ann Oncol 2003;14:110-115.
29. Ajani JA, Mansfield PF, Janjan N, et al.: Multi-institutional trial of preoperative chemoradiotherapy in patients with potentially resectable gastric carcinoma. J Clin Oncol 2004;22:2774-2780.
30. Ajani JA, Mansfield PF, Crane CH, et al.: Paclitaxel-based chemoradiotherapy in localized gastric carcinoma: Degree of pathologic response and not clinical parameters dictated patient outcome. J Clin Oncol 2005;23:1237-1244.
31. Ajani JA, Winter K, Okawara GS, et al.: Phase II trial of preoperative chemoradiation in patients with localized gastric adenocarcinoma (RTOG 9904): Quality of combined modality therapy and pathologic response. J Clin Oncol 2006;24:3953-3958.
32. Bentrem D, Gerdes H, Tang L, et al.: Clinical correlation of endoscopic ultrasonography with pathologic stage and outcome in patients undergoing curative resection for gastric cancer. Ann Surg Oncol 2007;14:1853-1859.
33. Skoropad V, Berdov B, Zagrebin V: Concentrated preoperative radiotherapy for resectable gastric cancer: 20-years follow-up of a randomized trial. J Surg Oncol 2002;80:72-78.
34. Zhang ZX, Gu XZ, Yin WB, et al.: Randomized clinical trial on the combination of preoperative irradiation and surgery in the treatment of adenocarcinoma of gastric cardia (AGC)-Report on 370 patients. Int J Radiat Oncol Biol Phys 1998;42:929-934.
35. Stahl M, Walz MK, Stuschke M, et al.: Phase III comparison of preoperative chemotherapy compared with chemoradiotherapy in patients with locally advanced adenocarcinoma of the esophagogastric junction. J Clin Oncol 2009;27:851-856.
36. Hartgrink HH, van de Velde CL, Putter H, et al.: Neo-adjuvant chemotherapy for operable gastric cancer: Long term results of the Dutch randomised FAMTX trial. Eur J Surg Oncol 2004;30:643-649.
37. Webb A, Cunningham D, Scarffe JH, et al.: Randomized trial comparing epirubicin, cisplatin, and fluorouracil versus fluorouracil, doxorubicin, and methotrexate in advanced esophagogastric cancer. Clin Oncol 1997;15:261-267.
38. Waters JS, Norman A, Cunningham D, et al.: Long-term survival after epirubicin, cisplatin and fluorouracil for gastric cancer: Results of a randomized trial. Br J Cancer 1999;80:269-272.
39. Boige V, Pignon J, Saint-Aubert B, et al.: Final results of a randomized trial comparing preoperative 5-fluorouracil (F)/ cisplatin(P) to surgery alone in adenocarcinoma of the stomach and lower esophagus (ASLE): FNLCC ACCORD07-FFCD 9703 trial. J Clin Oncol 2007;25:4510.
40. Bentrem D, Wilton A, Mazumdar M, et al.: The value of peritoneal cytology as a preoperative predictor in patients with gastric carcinoma undergoing a curative resection. Ann Surg Oncol 2005;12:347-3453.
41. Kuramoto M, Shimada S, Ikeshima S, et al.: Extensive intraoperative peritoneal lavage as a standard prophylactic strategy for peritoneal recurrence in patients with gastric carcinoma. Ann Surg 2009;250:242-246.
42. Catarci M, Carrara A: Perioperative chemotherapy for gastric cancer. Ann Surg Oncol 2008;15:1253.
43. Sarela AI, Lefkowitz R, Brennan MF, et al.: Selection of patients with gastric adenocarcinoma for laparoscopic staging. Am J Surg 2006;191:134-138.
44. Gold JS, Jaques DP, Bentrem DJ, et al.: Outcome of patients with known metastatic gastric cancer undergoing resection with therapeutic intent. Ann Surg Oncol 2007;14:365-372.
45. Kattan MW, Karpeh MS, Mazumdar M, et al.: Postoperative nomogram for disease-specific survival after an R0 resection for gastric carcinoma. J Clin Oncol 2003;21:3647-3650.
46. Lowy AM, Mansfield PF, Leach SD, et al.: Response to neoadjuvant chemotherapy best predicts survival after curative resection of gastric cancer. Ann Surg 1999;229:303-308.
47. Ott K, Sendler A, Becker K, et al.: Neoadjuvant chemotherapy with cisplatin, 5-FU, and leucovorin (PLF) in locally advanced gastric cancer: A prospective phase II study. Gastric Cancer 2003;6:159-167.
48. Park SR, Lee JS, Kim CG, et al.: Endoscopic ultrasound and computed tomography in restaging and predicting prognosis after neoadjuvant chemotherapy in patients with locally advanced gastric cancer. Cancer 2008;112:2368-2376.
49. Weber WA, Ott K, Becker K, et al.: Prediction of response to preoperative chemotherapy in adenocarcinomas of the esophagogastric junction by metabolic imaging. J Clin Oncol 2001;19:3058-3065.
50. Ott K, Weber WA, Lordick F, et al.: Metabolic imaging predicts response, survival, and recurrence in adenocarcinomas of the esophagogastric junction. J Clin Oncol 2006;24:4692-4698.
51. Lordick F, Ott K, Krause BJ, et al.: PET to assess early metabolic response and to guide treatment of adenocarcinoma of the oesophagogastric junction: The MUNICON phase II trial. Lancet Oncol 2007;8:797-805.
52. Becker K, Mueller JD, Schulmacher C, et al.: Histomorphology and grading of regression in gastric carcinoma treated with neoadjuvant chemotherapy. Cancer 2003;98:1521-1530.
53. Jhawer M, Coit D, Brennan M, et al.: Perineural invasion after preoperative chemotherapy predicts poor survival in patients with locally advanced gastric cancer: Gene expression analysis with pathologic validation. Am J Clin Oncol 2009;32:356-362.
54. Mansour JC, Tang L, Shah M, et al.: Does graded histologic response after neoadjuvant chemotherapy predict survival for completely resected gastric cancer? Ann Surg Oncol 2007;14:3412-3418.
55. Ott K, Vogelsang H, Mueller J, et al.: Chromosomal instability rather than p53 mutation is associated with response to neo-adjuvant cisplatin-based chemotherapy in gastric carcinoma. Clin Cancer Res 2003;9:2307-2315.
56. Johnston PG, Lenz HJ, Leichman CG, et al.: Thymidylate synthase gene and protein expression correlate and are associated with response to 5-fluorouracil in human colorectal and gastric tumors. Cancer Res 1995;55:1407-1412.
57. Lenz HJ, Leichman CG, Danenberg KD, et al.: Thymidylate synthase mRNA level in adenocarcinoma of the stomach: A predictor for primary tumor response and overall survival. J Clin Oncol 1996;14:176-182.
58. Metzger R, Leichman CG, Danenberg KD, et al.: ERCC1 mRNA levels complement thymidylate synthase mRNA levels in predicting response and survival for gastric cancer patients receiving combination cisplatin and fluorouracil chemotherapy. J Clin Oncol 1998;16:309-316.
59. Garcia I, Vizoso F, Martin A, et al.: Clinical significance of the epidermal growth factor receptor and HER2 receptor in resectable gastric cancer. Ann Surg Oncol 2003;10:234-241.
60. Lordick F, Jager D: Current status and future of chemotherapy and biochemotherapy in gastroesophageal cancers. Gastrointest Cancer Res 2008;2:187-197.